» Articles » PMID: 37122741

Exhausted T Cells Hijacking the Cancer-immunity Cycle: Assets and Liabilities

Overview
Journal Front Immunol
Date 2023 May 1
PMID 37122741
Authors
Affiliations
Soon will be listed here.
Abstract

T cell exhaustion is an alternative differentiation path of T cells, sometimes described as a dysfunction. During the last decade, insights of T cell exhaustion acting as a bottle neck in the field of cancer immunotherapy have undoubtedly provoked attention. One of the main drivers of T cell exhaustion is prolonged antigen presentation, a prerequisite in the cancer-immunity cycle. The umbrella term "T cell exhaustion" comprises various stages of T cell functionalities, describing the dynamic, one-way exhaustion process. Together these qualities of T cells at the exhaustion continuum can enable tumor clearance, but if the exhaustion acquired timeframe is exceeded, tumor cells have increased possibilities of escaping immune system surveillance. This could be considered a tipping point where exhausted T cells switch from an asset to a liability. In this review, the contrary role of exhausted T cells is discussed.

Citing Articles

Harnessing Epigenetics: Innovative Approaches in Diagnosing and Combating Viral Acute Respiratory Infections.

Saha A, Ganguly A, Kumar A, Srivastava N, Pathak R Pathogens. 2025; 14(2).

PMID: 40005506 PMC: 11858160. DOI: 10.3390/pathogens14020129.


Single-cell landscape of dynamic changes in CD8 T cells, CD4 T cells and exhausted T cells in hepatocellular carcinoma.

Liu R, Ye J, Wang J, Ma W, Qiu Z, Yu J Sci Rep. 2025; 15(1):4130.

PMID: 39900964 PMC: 11791069. DOI: 10.1038/s41598-025-88377-7.


TIGIT and PD-L1 co-blockade promotes clonal expansion of multipotent, non-exhausted antitumor T cells by facilitating co-stimulation.

Nutsch K, Banta K, Wu T, Tran C, Mittman S, Duong E Nat Cancer. 2024; 5(12):1834-1851.

PMID: 39681653 PMC: 11663793. DOI: 10.1038/s43018-024-00870-6.


Immune Checkpoint Inhibitor Therapy for Metastatic Melanoma: What Should We Focus on to Improve the Clinical Outcomes?.

Hossain S, Ly K, Sung Y, Braithwaite A, Li K Int J Mol Sci. 2024; 25(18).

PMID: 39337605 PMC: 11432671. DOI: 10.3390/ijms251810120.


Predictive Biomarkers and Resistance Mechanisms of Checkpoint Inhibitors in Malignant Solid Tumors.

Pavelescu L, Enache R, Rosu O, Profir M, Cretoiu S, Gaspar B Int J Mol Sci. 2024; 25(17).

PMID: 39273605 PMC: 11395316. DOI: 10.3390/ijms25179659.


References
1.
Woroniecka K, Chongsathidkiet P, Rhodin K, Kemeny H, Dechant C, Farber S . T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma. Clin Cancer Res. 2018; 24(17):4175-4186. PMC: 6081269. DOI: 10.1158/1078-0432.CCR-17-1846. View

2.
Pauken K, Sammons M, Odorizzi P, Manne S, Godec J, Khan O . Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science. 2016; 354(6316):1160-1165. PMC: 5484795. DOI: 10.1126/science.aaf2807. View

3.
Wu X, Zhang H, Xing Q, Cui J, Li J, Li Y . PD-1(+) CD8(+) T cells are exhausted in tumours and functional in draining lymph nodes of colorectal cancer patients. Br J Cancer. 2014; 111(7):1391-9. PMC: 4183848. DOI: 10.1038/bjc.2014.416. View

4.
Fitzgerald B, Connolly K, Cui C, Fagerberg E, Mariuzza D, Hornick N . A mouse model for the study of anti-tumor T cell responses in Kras-driven lung adenocarcinoma. Cell Rep Methods. 2021; 1(5). PMC: 8500377. DOI: 10.1016/j.crmeth.2021.100080. View

5.
Scott A, Dundar F, Zumbo P, Chandran S, Klebanoff C, Shakiba M . TOX is a critical regulator of tumour-specific T cell differentiation. Nature. 2019; 571(7764):270-274. PMC: 7698992. DOI: 10.1038/s41586-019-1324-y. View